How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

346 results for

Tipranavir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. In vitro activity against Plasmodium falciparum of antiretroviral drugs. Full Text available with Trip Pro

the concentrations achieved with standard dosing. The effects most likely to be clinically relevant were with HIV protease inhibitors. Of the tested compounds, activity was seen with lopinavir (2.7 to 2.9 μM), atazanavir (3.3 to 13.0 μM), saquinavir (5.0 to 12.1 μM), nelfinavir (6.5 to 12.1 μM), ritonavir (9.5 to 10.9 μM), tipranavir (15.5 to 22.3 μM), and amprenavir (28.1 to 40.8) but not darunavir. Lopinavir was active at levels well below those achieved with standard dosing of coformulated lopinavir-ritonavir

2011 Antimicrobial Agents and Chemotherapy

182. Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours

to interact with pantoprazole, including: The anti-fungal agents fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole; The antiviral agents: atazanavir, delavirdine, indinavir, nelfinavir, raltegravir, saquinavir, tipranavir; The anticoagulant agents: clopidogrel, dabigatran; The immunosuppressive agent: mycophenolate The anti-inflammatory agent: mesalamine Patients who are receiving oral pantoprazole or other PPI inhibitors may participate if these agents are discontinued at least 7 days

2010 Clinical Trials

183. IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

will be stratified by medication, HIV status and HIV antiretroviral therapy as follows: Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant (prescribed) efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a (prescribed) protease inhibitor (PI)* with concomitant ritonavir (at boosting doses) or lopinavir/ritonavir. *PI may be any of the following: atazanavir, darunavir, fosamprenavir, indinavir, saquinavir or tipranavir Amphetamine (...) / dextroamphetamine Subjects will be stratified by medication, HIV status and HIV antiretroviral therapy as follows: Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant (prescribed) efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a (prescribed) protease inhibitor (PI)* with concomitant ritonavir (at boosting doses) or lopinavir/ritonavir. *PI may be any of the following: atazanavir, darunavir, fosamprenavir, indinavir, saquinavir or tipranavir

2010 Clinical Trials

184. Study on Interleukin-7 (CYT107) in HIV Patients

not be enrolled. HIV-2, HTLV-1 or HTLV-2 seropositivity. Pregnant or lactating women. Women of childbearing potential must have a negative serum or urine pregnancy test within 1 week prior to study entry. Refusal or inability to practice contraception regardless of the gender of the patient. Hypertension with a resting systolic blood pressure > 140 or a resting diastolic blood pressure > 90 mm despite adequate antihypertensive treatment. Use of tipranavir/ritonavir (TPV/r) and Enfuvirtide (T-20). Contacts

2010 Clinical Trials

185. Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children

in this study is defined as an antiretroviral (ARV) regimen in a patient who has failure or intolerance to first line NNRTI-based therapy and second line PI-based therapy. Such regimens may contain new drugs or drug classes such as darunavir, tipranavir, etravirine and raltegravir The knowledge gained from this study will help the Thai government in planning its strategy to provide third line ARV therapy to children within the national program. Condition or disease Intervention/treatment This Study (...) may contain new drugs or drug classes such as darunavir, tipranavir, etravirine and raltegravir Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 56 participants Observational Model: Cohort Time Perspective: Other Official Title: Treatment Cohort of HIV-infected Children With Resistance or Intolerance to Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI) First Line and PI Second Line Antiretroviral Therapy Study Start Date : August 2010 Actual

2010 Clinical Trials

186. Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Tipranavir Full dose anticoagulation with warfarin (coumadin) or other vitamin K dependent anticoagulant. Low-dose prophylactic warfarin (i.e. 1mg per day port prophylaxis) is allowable. Low molecular heparin (e.g., danaparoid, dalteparin, tinzaparin, enoxaparin) is allowable if patient has been established on therapy. Have received an estimated dose of radiation therapy to >35% of the bone marrow. Patients previously exposed to mTOR inhibitors are permitted in phase 1A but not allowed in phase 1B

2010 Clinical Trials

187. Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

(single-arm study) The subjects in this arm will receive Maraviroc as treatment, while continuing their current antiretroviral medication regimen. Drug: Maraviroc FDA Recommended dosing will be used in this study. Subjects on an efavirenz or etravirine-based regimen will be dosed at 600 mg orally, twice per day, for 96 weeks. Subjects on a ritonavir-boosted protease inhibitor based regimen (except for tipranavir/ritonavir) will be dosed at 150 mg orally, twice per day, for 96 weeks. Subjects

2010 Clinical Trials

188. HIV-1 Protease Mutations and Protease Inhibitor Cross Resistance. Full Text available with Trip Pro

to atazanavir; 1,265 isolates had been tested for susceptibility to tipranavir; and 642 isolates had been tested for susceptibility to darunavir. We applied least-angle regression (LARS) to the 200 most common mutations in the data set and identified a set of 46 mutations associated with decreased PI susceptibility of which 40 were not polymorphic in the eight most common HIV-1 group M subtypes. We then used least-squares regression to ascertain the relative contribution of each of these 46 mutations

2010 Antimicrobial Agents and Chemotherapy

189. Novel Protease Inhibitors (PIs) Containing Macrocyclic Components and 3(R),3a(S),6a(R)-bis-Tetrahydrofuranylurethane (bis-THF) That Are Potent Against Multi-PI-Resistant HIV-1 Variants In Vitro. Full Text available with Trip Pro

, M46L, V82I, and I84V mutations remained relatively sensitive to PIs, including darunavir, with the EC50s being 3- to 8-fold-greater than the EC50 of each drug for HIV-1NL4-3. Interestingly, HIV216-0.16 microM had 10-fold increased sensitivity to tipranavir. Analysis of the protein-ligand X-ray structures of GRL-216 revealed that the macrocycle occupied a greater volume of the binding cavity of protease and formed greater van der Waals interactions with V82 and I84 than darunavir. The present data

2010 Antimicrobial Agents and Chemotherapy

190. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience. (Abstract)

. The incremental annual cost per additional patient achieving undetectable plasma HIV-RNA levels with DRV/r versus control PI-based HAART in POWER 1 and 2 (£4148) compared favourably with that determined for enfuvirtide (£137, 740; TORO trials) and tipranavir/ritonavir (£32,176; RESIST) versus control therapy.DRV/r-based HAART provided consistent reductions in the cost of achieving undetectable plasma HIV-RNA levels compared with control PI-based therapy in highly treatment-experienced patients across various

2010 PharmacoEconomics Controlled trial quality: uncertain

191. Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens

for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: HIV-1 infected adults (=/+18 years old). Patients having a diagnosis of HIV infection, on stable HAART including: 2 NRTI/NtRTIs plus one of the following : 1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir) or ATV/unboosted (in a regimen without tenofovir) 1 NNRTI (nevirapine or efavirenz), raltegravir or maraviroc Undetectable plasma HIV-1 RNA (VL < 50

2009 Clinical Trials

192. Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

approach. Condition or disease Intervention/treatment Phase HIV HIV Infections Drug: maraviroc Drug: control group Phase 4 Detailed Description: This is a 48 week randomized, prospective, controlled, open-label, proof-of-concept pilot clinical trial. Patients with HIV-1 infection on HAART regimen including 2 NRTI/NtRTIs plus one of the following : 1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir) or ATV/unboosted (...) the NNRTI/PI to maraviroc to switch from the NNRTI/PI to maraviroc Drug: maraviroc HAART regimen including 2 NRTI/NtRTIs plus maraviroc Active Comparator: to continue with the same approach to continue with the same approach Drug: control group HAART regimen including 2 NRTI/NtRTIs plus one of the following : 1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir) or ATV/unboosted (in a regimen without tenofovir) or 1 NNRTI

2009 Clinical Trials

193. Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer

, including any of the following: Ketoconazole Itraconazole Clarithromycin Erythromycin Diltiazem Verapamil Delavirdine Indinavir Saquinavir Ritonavir Atazanavir Nelfinavir At least 12 days since prior and no concurrent potent CYP3A inducers, including any of the following: Rifampin Rifabutin Carbamazepine Phenobarbital Phenytoin St. John's wort Efavirenz Tipranavir Concurrent radiotherapy allowed provided sunitinib malate is stopped one day before and resumed one day after radiotherapy Concurrent

2009 Clinical Trials

194. A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

Study Description Go to Brief Summary: The aim of this trial is to evaluate the safety and virological and immunological efficacy of Aptivus in treatment-experienced patients with advanced HIV-1 infection who had developed resistance to more than one protease inhibitor. Condition or disease Intervention/treatment HIV Infections Drug: Tipranavir Drug: ritonavir Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 42 participants Observational Model (...) : Cohort Time Perspective: Prospective Official Title: A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Tipranavir (Aptivus®) Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice. Study Start Date : September 2009 Actual Primary Completion Date : July 2011 Actual Study Completion Date : July 2011 Resource links provided by the National Library of Medicine related topics: available for: Groups

2009 Clinical Trials

195. The St. Marys and The Mater Switch Study

: No Criteria Inclusion Criteria: HIV-1 infected males or females Between 18 and 65 years of age Signed informed consent Currently receiving a stable antiretroviral regimen comprising of: two licensed NRTIs including abacavir and/or didanosine any licensed boosted protease inhibitor at any dose (excluding tipranavir*) Undetectable plasma HIV RNA to less than 50 copies/mL for at least 24 weeks prior to screening Availability of stored plasma with which to perform a tropism assay CCR5 tropic HIV virus based

2009 Clinical Trials

196. Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.

treated with darunavir Patient treated with tipranavir, enfuvirtide, raltegravir, etravirine, and/or maraviroc Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00849160 Locations Layout table for location information France Centre Hospitalier

2009 Clinical Trials

197. Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

; Atazanavir, Reyataz; Fosamprenavir, Telzir, FPV; Darunavir, Prezista, TMC114; Tipranavir, Aptivus, TPV; Indinavir, Crixivan; abacavir; raltegravir, Isentress; Enfuvirtide, Fuzeon; Maraviroc, Celsentri; dolutegravir; elvitegravir/cobicistat; rilpivirine, TAF, darunavir/cobicistat Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 176 participants Observational Model: Case-Crossover Time Perspective: Prospective Official Title: Study on Pharmacokinetics (...) (Adult, Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Sampling Method: Non-Probability Sample Study Population HIV-infected pregnant women using at least one of the following antiretroverial agents: Etravirine, Intelence, TMC125; Emtricitabine, Emtriva or FTC; Tenofovir, Viread, TDF; Atazanavir, Reyataz; Fosamprenavir, Telzir, FPV; Darunavir, Prezista, TMC114; Tipranavir, Aptivus, TPV; Indinavir, Crixivan; Raltegravir, Isentress; Enfuvirtide, Fuzeon; Maraviroc

2009 Clinical Trials

198. Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer

, miconazole, itraconazole, erythromycin, clarithromycin, diltiazem, nefazodone, voriconazole, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, delavirdine) No concurrent known CYP3A4 or CYP1A2 inducers (i.e., carbamazepine, dexamethasone, felbamate, omeprazole, efavirenz, tipranavir, phenobarbital, phenytoin, primidone, rifabutin, rifampicin, St. John's wort) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may

2009 Clinical Trials

199. Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

, rifabutin, rifampin, tipranavir, ritonavir, and St. John?s wort are not eligible; the topical use of these medications (if applicable) is allowed Patients with known interstitial fibrosis or interstitial lung disease are not eligible Patients with a known history of myocardial infarction or cerebrovascular accident are not eligible Patients with central nervous system (CNS) tumors or known CNS metastases are not eligible; patients with a history of CNS metastases that have been surgically resected

2009 Clinical Trials

200. An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options. An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2009 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>